Biomarkers of acute rejection following cardiac transplantation

Biomarkers in Medicine

Volumn 8, Issue 6, 2014, Pages 815-832

  McMinn, Jenna F ^a   Lang, Ninian N ^a   McPhadden, Allan ^b   Payne, John R ^a   Petrie, Mark C ^a   Gardner, Roy S ^a  

^a GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

^b SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

biomarkers; BNP; cardiac transplantation; endomyocardial biopsy; prognosis; rejection

Indexed keywords

ALLOGRAFT INFLAMMATORY FACTOR 1; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C4; COMPLEMENT MEMBRANE ATTACK COMPLEX; CXCL9 CHEMOKINE; D DIMER; FIBRINOGEN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NITRATE; PADGEM PROTEIN; SIALIC ACID; THROMBOMODULIN; THROMBOXANE A2; TROPONIN I; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A;

ACUTE GRAFT REJECTION; ANTIBODY MEDIATED REJECTION; CARDIAC GRAFT REJECTION; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CARDITIS; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; GENE EXPRESSION PROFILING; HEART INJURY; HEART MUSCLE BIOPSY; HEART MUSCLE CELL; HEART STRESS; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; INTRAMYOCARDIAL ELECTROGRAM; NONHUMAN; RADIONUCLIDE SCINTIGRAPHY; REVIEW; SCINTIGRAPHY; BLOOD; GRAFT REJECTION; MORTALITY; PROGNOSIS;

BIOLOGICAL MARKERS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS;

EID: 84907272940     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.14.56     Document Type: Review

References (134)

1. Stehlik J, Edwards LB, Kucheryavaya AY et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report-2011. J. Heart Lung Transplant. 30(10), 1078-1094 (2011).
2. Stehlik J, Edwards LB, Kucheryavaya AY et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-ninth adult heart transplant report-2012. J. Heart Lung Transplant. 31(10), 1053-1064 (2012).
3. Stehlik J, Edwards LB, Kucheryavaya AY et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report 2010. J. Heart Lung Transplant. 29(10), 1089-1103 (2009).
4. Miller CA, Fildes JE, Ray SG et al. Review: non-invasive approaches for the diagnosis of acute cardiac allograft rejection. Heart 99(7), 445-453 (2013).
5. Costanzo MR, Dipchand A, Starling R et al. The International Society for Heart and Lung Transplantation guidelines for the care of heart transplant recipients. J. Heart Lung Transplant. 29(8), 914-956 (2010).
6. Angelini A, Andersen CB, Bartoloni G et al. A web-based pilot study of inter-pathologist reproducibility using ISHLT 2004 working formulation for biopsy diagnosis of cardiac allograft rejection: The European experience. J. Heart Lung Transplant. 30(11), 1214-1220 (2011).
7. Crespo-Leiro MG, Zuckermann A, Bara C et al. Concordance among pathologists in the second Cardiac Allograft Rejection Gene Expression Observational Study (CARGO II). Transplantation 94(11), 1172-1177 (2012).
8. Subherwal S, Kobashigawa JA, Cogert G et al. Incidence of acute cellular rejection and non-cellular rejection in cardiac transplantation. Transplant. Proc. 36(10), 3171-3172 (2004).
9. Patel JK, Kittleson M, Kobashigawa JA. Cardiac allograft rejection. Surgeon 9(3), 160-167 (2011).
10. Crudele V, Picascia A, Infante T, Grimaldi V, Maiello C, Napoli C. Repeated immune and non immune insults to the graft after heart transplantation. Immunol. Lett. 141(1), 18-27 (2011).
11. Kobashigawa J, Mehra M, West L et al. Report from a consensus conference on the sensitized patient awaiting heart transplantation. J. Heart Lung Transplant. 28(3), 213-225 (2009).
12. Uber WE, Self SE, Van Bakel AB, Pereira NL. Acute antibody-mediated rejection following heart transplantation. Am. J. Transplant. 7(9), 2064-2074 (2007).
13. Afzali B, Lechler RI, Hernandez-Fuentes MP. Allorecognition and the alloresponse: clinical implications. Tissue Antigens 69(6), 545-556 (2007).
14. Stewart S, Winters GL, Fishbein MC et al. Revision of the 1990 working formulation for the standardisation of nomenclature in the diagnosis of heart rejection. J. Heart Lung Transplant. 24(11), 1710-1720 (2005).
15. Berry GJ, Burke MM, Andersen C et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardisation of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J. Heart Lung Transplant. 32(12), 1147-1162 (2013).
16. Berry GJ, Angelini A, Burke MM et al. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011). J. Heart Lung Transplant. 30(6), 601-611 (2011).
17. Fishbein GA, Fishbein MC. Morphological and imunohistochemical findings in antibody-mediated rejection of the cardiac allograft. Hum. Immunol. 73(12), 1213-1217 (2012).
18. Wu GW, Kobashigawa JA, Fishbein MC et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J. Heart Lung Transplant. 28(5), 417-422 (2009).
19. Kfoury AG, Hammond ME, Snow GL et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. J. Heart Lung Transplant. 28(8), 781-784 (2009).
20. Kobashigwa J, Crespo-Leiro MG, Ensminger SM et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J. Heart Lung Transplant. 30(3), 252-269 (2011).
21. Michaels PJ, Espejo ML, Kobashigawa J et al. Humoral rejection in cardiac transplantation: risk factors, haemodynamic consequences and relationship to transplant coronary artery disease. J. Heart Lung Transplant. 22(1), 58-69 (2003).
22. Hammond ME, Stehlik J, Snow G et al. Utility of histologic parameters in screening for antibody-mediated rejection of the cardiac allograft: a study of 3,170 biopsies. J. Heart Lung Transplant. 24(12), 2015-2021 (2005).
23. Roshanali F, Mandegar MH, Bagheri J et al. Echo rejection score: new echocardiographic approach to diagnosis of heart transplant rejection. Eur. J Cardiothorac. Surg. 38(2), 176-180 (2010).
24. Almenar L, Osa A, Martinex-Dolz L et al. Echocardiographic evaluation of the evolutionary changes after heart transplantation. Transplant. Proc. 38(8), 2575-2576 (2006).
25. Dandel M, Hummel M, Muller J et al. Reliability of tissue Doppler wall motion monitoring after heart transplantation for replacement of invasive routine screenings by optimally timed cardiac biopsies and catheterisations. Circulation 104(12 Suppl. 1), 1184-1191 (2001).
26. Palka P, Lange A, Galbraith A et al. The role of and right ventricular early diastolic Doppler tissue echocardiographic indices in the evaluation of acute rejection in orthotopic heart transplant. J. Am. Soc. Echocardiogr. 18(2), 107-115 (2005).
27. Mankad S, Murali S, Komos RL et al. Evaluation of the potential role of color-coded tissue Doppler echocardiography in the detection of allograft rejection in heart transplant recipients. Am. Heart J. 138(4 Pt 1), 721-730 (1999).
28. Stengel SM, Allemann Y, Zimmerli M et al. Doppler tissue imaging for assessing left ventricular diastolic dysfunction in heart transplant rejection. Heart 86(4), 423-427 (2001).
29. Sun JP, Abdallla IA, Asher CR et al. Non-invasive evaluation of orthotopic heart transplant rejection by echocardiography. J. Heart Lung Transplant. 24(2), 160-165 (2005).
30. Fabregas RI, Crespo-Leiro MG, Muniz J et al. Usefulness of pulsed Doppler tissue imaging for noninvasive detection of cardiac rejection after heart transplantation. Eur. J. Echocardiogr. 8(6), 213-221 (2007).
31. Kato TS, Oda N, Hashimura K et al. Strain rate imaging would predict sub-clinical acute rejection in heart transplant recipients. Eur. J. Cardiothorac. Surg. 37(5), 1104-1110 (2010).
32. Sato T, Kato TS, Kamamura K et al. Utility of left ventricular systolic torsion derived from 2-dimensional speckle-tracking echocardiography in monitoring acute cellular rejection in heart transplant recipients. J. Heart Lung Transplant. 30(5), 536-543 (2011).
33. Roshanali F, Mandegar MH, Bagheri J et al. Echo rejection score: new echocardiographic approach to diagnosis of heart transplant rejection. Eur. J Cardiothorac. Surg. 38(2), 176-180 (2010).
34. Mena C, Wencher D, Krumholz HM et al. Detection of heart transplant rejection in adults by echocardiographic diastolic indices: a systematic review of the literature. J. Am. Soc. Echocardiogr. 19(10), 1295-1300 (2006).
35. Prakash A, Printz BF, Lamour JM et al. Myocardial performance index in paediatric patients after cardiac transplantation. J. Am. Soc. Echocardiography. 17(5), 439-442 (2004).
36. Leonard GT Jr, Fricker FJ, Pruett D et al. Increased myocardial performance index correlates with biopsy-proven rejection in paediatric heart transplant recipients. J. Heart Lung Transplant. 25(1), 61-66 (2006).
37. Eleid MF, Caracciolo G, Cho EJ et al. Natural history of left ventricular mechanics in transplanted hearts: relationships with clinical variables and genetic expression profiles of allograft rejection. JACC Cardiovasc. Imaging 3(10), 989-1000 (2010).
38. Angermann CE, Nassau K, Stempfle HU et al. Recognition of acute cardiac allograft rejection from serial integrated backscatter analyses in human orthotopic heart transplant recipients. Comparison with conventional echocardiography. Circulation 95(1), 140-150 (1997).
39. Marie PY, Angioi M, Carteaux JP et al. Detection and prediction of acute heart transplant rejection with the myocardial T2 determination provided by a black-blood magnetic resonance imaging sequence. J. Am. Coll. Cardiol. 37(3), 825-831 (2001).
40. Wisenberg G, Pflugfelder PW, Kostuk WJ et al. Diagnostic applicability of magnetic resonance imaging in assessing human cardiac allograft rejection. Am. J. Cardiol. 60(1), 130-136 (1987).
41. Taylor AJ, Vaddadi G, Pfluger H et al. Diagnostic performance of multisequential cardiac magnetic resonance imaging in acute cardiac allograft rejection. Eur. J. Heart. Fail. 12(1), 45-51 (2010).
42. Steen H, Merten C, Refle S et al. Prevalence of different gadolinium enhancement patterns in patients after heart transplantation. J. Am. Coll. Cardiol. 52, 1160-1167 (2008).
43. Wu YL, Ye Q, Foley LM et al. In situ labelling of immune cells with iron oxide particles: an approach to detect organ rejection by cellular MRI. Proc. Natl Acad. Sci. USA 103, 1852-1857 (2006).
44. Penno E, Johnsson C, Johansson L et al. Comparison of ultrasmall superparamagnetic iron oxide particles and low molecular weight contrast agents to detect rejecting transplanted hearts with magnetic resonance imaging. Invest. Radiol. 40, 648-654 (2005).
45. Penno E, Johannson L, Ahlstrom H et al. Ultrasmall iron oxide particle contrast agent and MRI can be used to monitor the effect of anti-rejection treatment. Transplantation 84, 374-379 (2007).
46. Kanno S, Wu Y-JL, Lee PC et al. Macrophage accumulation associated with rat cardiac allograft rejection detected by magnetic resonance imaging with ultrasmall superparamagnetic iron oxide particles. Circulation 104, 934-938 (2001).
47. Hesse B, Mortensens SA, Folke M et al. Ability of antimyosin scintigraphy monitoring to exclude acute rejection during the first year after heart transplantation. J. Heart Lung Transplant. 14, 23-31 (1995).
48. Rubin PJ, Hartman JJ, Hasapes JP et al. Detection of cardiac transplant rejection with 111In-labelled lymphocytes and gamma scintigraphy. Circulation 94, I298-303 (1996).
49. Kown MH, Strauss HW, Blankenberg FG et al. In vivo imaging of acute cardiac rejection in human patients using (99m)technetium labelled annexin v. Am. J. Transplant. 1, 270-277 (2001).
50. Gierthmuehlen M, Sommer P, Zuhayra M et al. Imaging of acute heart-transplant rejection using 99m-technetium labelled oligonucleotides against interleukin-2 mma in rats. Eur. J. Cardiothorac. Surg. 37, 1111-1116 (2010).
51. Tenderich G, Jahanyar J, Zitterman A, Schleithoff SS, Wlost S, Korfer R. Predictive value of ECG changes for acute cardiac rejections in heart transplant recipients. Med. Lin. 101, 99-106 (2006).
52. Keren A, Gillis AM, Freedman RA et al. Heart transplant rejection monitored by signal-averaged electrocardiography and patients receiving cyclosporine. Circulation 70, l124-l129 (1984).
53. Cooper DK, Charles RG, Rose AG et al. Does the electrocardiogram detect early acute heart rejection. J. Heart Transplant. 4, 546-549 (1985).
54. Valentino VA, Ventura HO, Abi-Samra FM, Meter CH, Price HL. The signal-averaged electrocardiogram in cardiac transplantation. A noninvasive marker of acute allograft rejection. Transplantation 53, 124-127 (1992).
55. Graceffo MA, O'Rourke RA. Cardiac transplant rejection is associated with a decrease in the high-frequency component of the high-resolution, signal-averaged electrocardiogram. Am. Heart J. 132, 820-826 (1996).
56. Lacroix D, Kacet S, Savard P et al. Signal-average electrocardiography and detection of heart transplant rejection: comparison of time and frequency domain analyses. J. Am. Coll. Cardiol. 19, 553-558 (1992).
57. Schweiger M, Wasler A, Prenner G, Rauchegger G, Kniepeiss D, Tscheiliessnigg KH. Lessons learned with noninvasive cardiac monitoring for acute rejection. Transplant. Proc. 39, 3303-3305 (2007).
58. Schweiger M, Wasler A, Prenner G, Tripold M, Tauchegger G, Tscheiliessnigg K. The prognostic validity of the ventricular evoked response (VER) signals in cardiac transplantation. J. Heart Lung Transplant. 11, 1730-1735 (2005).
59. Schaffellner S, Grasser B, Kniepeiss D et al. Non-invasive heart monitoring after heart transplantation with CHARM (Computerised Heart Allograft Recipient Monitoring): clinical experience. Transplant. Proc. 32, 642-644 (2000).
60. Grasser B, Iberer F, Schreier G et al. Non-invasive cardiac allograft monitoring: the Graz experience. J. Heart Lung Transplant. 19, 653-659 (2000).
61. Grasser B, Iberer F, Schreier G et al. Computerised heart allograft-recipient monitoring: a multicentre study. Transp. Int. 16, 225-230 (2003).
62. Bourge R, Eisen H, Hershberger R et al. Non-invasive rejection monitoring of cardiac transplants using high resolution intramyocardial electrograms: initial us multicentre experience. Pacing Clin. Electrophysiol. 21, 2338-2344 (1998).
63. Grasser B, Iberer F, Schaffellner S et al. Non-invasive graft monitoring after heart transplantation: rationale to reduce the number of endomyocardial biopsies. Transplant. Int. 13(Suppl.1), 225 (2000).
64. Thygesen K, Alpert JS, White HD et al. Universal definition of myocardial infarction. Circulation 116, 2634-2653 (2007).
65. Sato Y, Fujiwara H, Takatsu Y. Cardiac troponin and heart failure in the era of high-sensitive assays. J. Card. 60, 160-167 (2012).
66. Wallace TW, Abdullah SM, Drazner MH et al. Prevalence and determinants of troponin T elevation in the general population. Circulation 113, 1958-1965 (2006).
67. Gleissner CA, Zehelein J, Sack FU, Schnabel P, Haass M, Denger TJ. Extended experience and subgroup analysis using cardiac troponin T for rejection monitoring after heart transplantation. Transplant. Proc. 34, 2178-2180 (2002).
68. Siaplaouras J, Thul J, Kramer U, Bauer J, Schranz D. Cardiac troponin I: a marker of acute heart rejection in infant and child heart recipients? Pediatr. Transplant. 7, 43-45 (2003).
69. Mullen JC, Bently MJ, Scherr KD et al. Troponin T and I are not reliable markers of cardiac transplant rejection. Eur. J Cardiothorac. Surg. 22, 233-237 (2002).
70. Chance JJ, Segal JB, Wallerson G et al. Cardiac troponin T and C-reactive protein as markers of acute cardiac allograft rejection. Clin. Chim. Acta 213, 31-39 (2001).
71. Labarrere CA, Nelson DR, Cox CJ, Pitts D, Kirlin P, Halbrook H. Cardiac-specific troponin I levels and risk of coronary artery disease and graft failure following heart transplantation. JAMA 284, 457-464 (2000).
72. Dyer AK, Barnes AP, Fixler DE et al. Use of a highly sensitive assay for cardiac troponin T and N-terminal pro-brain natriuretic peptide to diagnose acute rejection in pediatric cardiac transplant recipients. Am. Heart J. 163, 595-600 (2012).
73. Erbel C, Taskin R, Doesche A, Dengler T et al. High-sensitive troponin T measurements early after heart transplantation predict short-and long-term survival. Transpl. Int. 26, 267-272 (2013).
74. Daniels LB, Maisel AS. Natriuretic peptides. J. Am. Coll. Cardiol. 50, 2357-2368 (2007).
75. Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J Med. 347, 161-167 (2002).
76. Januzzi JL Jr, Camargo CA, Anwaruddin S et al. The N-terminal Pro-BNP Investigation of Dyspnoea in the Emergency Department (PRIDE) Study. Am. J. Cardiol. 95, 948-954 (2005).
77. Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J. Am. Coll. Cardiol. 49, 1943-1950 (2007).
78. Kruger S, Graft J, Kunz D, Stickel T, Hanrath P, Janssens U. Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J. Am. Coll. Cardiol. 40, 718-722 (2002).
79. Richards AM, Doughty R, Nicholls MG et al. Prognostic utility and prediction of benefit from carvedilol in chronic ischaemic left ventricular fysfunction. J. Am. Coll. Cardiol. 37, 1781-1787 (2001).
80. Jourdain P, Jondeau G, Funck F et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J. Am. Coll. Cardiol. 49, 1733-1739 (2007).
81. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide concentrations. Lancet 355, 1126-1130 (2000).
82. Hervas I, Arnau MA, Almenar L et al. Ventricular natriuretic peptide (BNP) in heart transplantation: BNP correlation with endomyocardial biopsy, laboratory and haemodynamic measures. Lab. Invest. 84, 138-145 (2004).
83. Bader FM, Rogers RK, Kfoury AG et al. Time-dependent changes in B-type natriuretic peptide after heart transplantation: correlation with allograft rejection and function. Congest. Heart Fail. 15, 63-67 (2009).
84. Arnau-Vives MA, Almena L, Hervas I et al. Predictive value of brain natriuretic peptide in the diagnosis of heart transplant rejection. J. Heart Lung Transplant. 23, 850-855 (2004).
85. Cuppoletti A, Roig E, Pérez-Villa F et al. Value of NT-proBNP determinations in the follow-up of heart transplantation. J. Transplant. Proc. 37, 4033-4035 (2005).
86. Gardner RS, Chong KS, Murday AJ, Morton JJ, McDonagh TA. N-terminal brain natriuretic peptide is predictive of death after cardiac transplantation. Heart 92, 121-123 (2006).
87. Masters RG, Davies RA, Veinot JP et al. Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans. Circulation 100, 287-291 (1999).
88. Park MH, Scott RL, Uber PA et al. Bedside B-type natriuretic peptide and acute non-cellular cardiac allograft rejection. J. Heart Lung Transplant. 21, 613-614 (2002).
89. Almenar L, Hervas I, Martines-Dolz L et al. The value of brain natriuretic pepetide for the diagnosis of heart transplant rejection. Transplant. Proc. 34, 174-175 (2002).
90. Wu AH, Johnson ML, Aaronson KD et al. Brain natriuretic pepetide predicts serious cardiac allograft rejection independent of haemodynamic measurements. J. Heart Lung Transplant. 24, 52-57 (2005).
91. Avello N, Prieto B, Molina BD, Rodriguez-Lambert JL, Alvarez FV. Clinical utility of NT-proBNP levels in late heart transplantation patients. Clin. Chim. Acta 411, 161-166 (2010).
92. Damodaran A, Dardas T, Wu AH et al. Changes in serial B-type natriuretic peptide independently predict cardiac allograft rejection. J. Heart Lung Transplant. 31, 708-714 (2012).
93. Garrido IP, Pascual-Figal DA, Nicolas F et al. Usefulness of serial monitoring of B-type natriuretic peptide for the detection of acute rejection after heart transplantation. Am. J. Cardiol. 103, 1149-1153 (2009).
94. Kittleson MM, Skojec DV, Wittstein IS et al. The change in B-type natriuretic peptide levels over time predicts significant rejection in cardiac transplant patients. J. Heart Lung Transplant. 28, 704-709 (2009).
95. Venugopal SK, Deveraj S, Jialal I. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr. Opin. Nephrol. Hypertens. 14, 33-37 (2005).
96. Anand IS, Latini R, Florea VG et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 112, 1428-1434 (2005).
97. Martinez-Dolz L, Almenar L, Reganon E et al. What is the best biomarker for diagnosis of rejection in heart transplantation? Clin. Transplant. 23, 672-680 (2009).
98. Wang CW, Steinhubl SR, Castellani WJ et al. Inability of serum myocyte death markers to predict acute cardiac allograft rejection. Transplantation 62, 1938-1941 (1996).
99. Sanchez-Soriano RM, Almenar L, Martinez-Dolz L et al. Diagnostic usefulness of inflammatory markers in acute cellular rejection after heart transplantation. Transpl. Proc. 38, 2569-2571 (2006).
100. George JF, Kirklin JF, Naftel DC et al. Serial measurements of interleukin-6, interleukin-8, tumour necrosis factor-alpha, and soluble vascular cell adhesion molecule-1 in the peripheral blood plasma of human cardiac allograft recipients. J. Heart Lung Transplant. 16, 1046-1053 (1997).
101. Brunet M. Cytokines as predictive biomarkers of alloreactivity. Clin. Chim. Acta 413, 1354-1358 (2012).
102. Grant SC, Lamb WR, Brooks NH et al. Serum cytokines in human heart transplant recipients. Is there a relationship to rejection? Transplantation 62, 480-491 (1996).
103. Ypsilantis E, Key T, Bradley JA et al. Soluble CD30 levels in recipients undergoing heart transplantation do not predict post-transplant outcome. J. Heart Lung Transplant. 28, 1206-1210 (2009).
104. Spiridon C, Hunt J, Mack M et al. Evaluation of soluble CD30 as an immunologic marker in heart recipients. Transplant. Proc. 38, 3689-3691 (2006).
105. Nikaein A, Spiridon C, Hunt J et al. Pre-transplant level of soluble CD30 is associated with infection after heart transplantation. Clin. Transplant. 21, 744-747 (2007).
106. Tible M, Loupy A, Vernerey D et al. Pathologic classification of antibody-mediated rejection correlates with donor-specific antibodies and endothelial cell activation. J. Heart Lung Transplant. 32, 769-776 (2013).
107. Nath DS, Angaswamy N, Basha HI et al. Donor-specific antibodies to human leukocyte antigens are associated with and precede antibodies to major histocompatibility complex class I-related chain A in antibody-mediated rejection and cardiac allograft vasculopathy after human cardiac transplantation. Hum. Immunol. 71, 1191-1196 (2010).
108. Zhang Q, Cecka JM, Gjertson DW et al. HLA and MICA: targets of antibody-mediated rejection in heart transplantation. Transplantation 91, 1153-1158 (2011).
109. Reinsmoen NL, Lai CH, Miocha J et al. Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome. Transplantation 97, 595-601 (2014).
110. Hiemann NE, Meyer R, Wellnhofer E et al. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation 94, 919-924 (2012).
111. Weinberg EO, Shimpo M, Hurwitz S et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107, 721-726 (2003).
112. Shimpo M, Morrow DA, Weinberg EO et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 109, 2186-2190 (2004).
113. Januzzi JL, Horne BD, Moore SA et al. Interleukin receptor family member ST2 concentrations in patients following heart transplantation. Biomarkers 18, 250-256 (2013).
114. Pascual-Figal DA, Garrido IP, Blanco R et al. Soluble ST2 is a marker for acute cardiac allograft rejection. Soluble ST2 is a marker for acute cardiac allograft rejection. Ann. Thorac. Surg. 92, 2118-2124 (2011).
115. Sanchez-Soriano RM, Almenar L, Martinez-Dolz L et al. Diagnostic usefulness of inflammatory markers in acute cellular rejection after heart transplantation. Transpl. Proc. 38, 2569-2571 (2006).
116. Brandacher G, Cakar F, Winkler C et al. Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation. Kidney Int. 71, 60-67 (2007).
117. Suarez-Fuentetaja N, Domenech-Garcia N, Paniagua-Martin MJ et al. Indoleamine 2-3 dioxygenase activity could be an early marker of graft rejection in heart transplantation. Transplant Proc. 44, 2645-2648 (2012).
118. Fahmy NM, Yamani MH, Startling RC et al. Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants. Transplantation 75, 72-78 (2003).
119. Karason K, Jernas M, Hagg DA, Svensson PA. Evaluation of CXCL9 and CXCL10 as circulating biomarkers of human cardiac allograft rejection. BMC Cardiovasc. Disord. 19, 6-29 (2006).
120. Zhou X, He Z, Henegar J, Allen B, Bigler S. Expression of allograft inflammatory factor-1 (AIF-1) in acute cellular rejection of cardiac allografts. Cardiovasc. Pathol. 20, e177-e184 (2011).
121. Utans U, Quist WC, McManus BM et al. Allograft inflammatory factor-1. A cytokine-responsive macrophage molecule expressed in transplanted human hearts. Transplantation 61, 1387-1392 (1996).
122. Autieri MV, Kelemen S, Thomas BA, Feller ED, Goldman BI, Eisen HJ. Allograft inflammatory factor-1 expression correlates with cardiac rejection and development of cardiac allograft vasculopathy. Circulation 106, 2218-2223 (2002).
123. Vallhonrat H, Williams WW, Dec GW et al. Complement activation products in plasma after heart transplantation in humans. Transplantation 71, 1308-1353 (2001).
124. Segal JB, Kasper EK, Rohde C et al. Coagulation markers predicting cardiac transplant rejection. Transplantation 72, 233-237 (2001).
125. Zhao Y, Katz NM, Kefrak EA, Foegh ML. Urinary thromboxane B2 in cardiac transplant patients as a screening method of rejection. Prostaglandins 54, 881-889 (1997).
126. Aharinejad S, Krenn K, Zuckermann A et al. Serum matrix metalloprotease-1 and vascular endothelial growth factor-a predict cardiac allograft rejection. Am. J. Transplant. 9, 149-159 (2009).
127. Benvenuti C, Bories PN, Loisance D. Increased serum nitrate concentration in cardiac transplant patients. A marker for acute allograft cellular rejection. Transplantation 61, 734-739 (1996).
128. Edwards SW, Nurcombe HL, Hart CA. Oxidative inactivation of myeloperoxidase released from human neutrophils. Biochem. J. 245, 925-928 (1987).
129. Hasegawa T, Iwanaga K, Hultquist DE et al. Suppression of nitrosative and oxidative stress to reduce cardiac allograft vasculopathy. Am. J. Physiol. Heart Circ. Physiol. 296, H1007-H1016 (2009).
130. Koestenbauer S, Stiegler P, Stadlbauer V et al. Myeloperoxidase and carbonyl proteins: promising markers for non-invasive monitoring of graft rejection after heart transplantation. J. Heart Lung Transplant. 29, 1352-1357 (2010).
131. Phillips M, Boehmer JP, Cataneo RN et al. Heart allograft rejection: detection with breath alkanes in low levels (the HARD-BALL study). J. Heart Lung Transplant. 23, 701-708 (2004).
132. Ling X, Xiong J, Liang W et al. Can immune cell function assay identify patients at risk of infection or rejection? A meta-analysis. Transplantation 93, 737-743 (2012).
133. Deng MC, Eisen HJ, Mehra MR et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am. J. Transplant. 6, 150-160 (2006).
134. Pham MX, Teuteberg JJ, Kfoury AG et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N. Engl. J Med. 362, 1890-1900 (2010).